1. Where Do We Go from Here?

   • Ronald C. Petersen

   Editorial 05 April 2022 Pages: 188 - 189

2. The ‘Aducanumab Story’: Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis’ or Mark a New Beginning?

   • Zaven S. Khachaturian

   Editorial 05 April 2022 Pages: 190 - 192

3. Aducanumab Trials EMERGE But Don’t ENGAGE

   • Lon S. Schneider

   Editorial 05 April 2022 Pages: 193 - 196

4. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

   • Samantha Budd Haeberlein
   • P.S. Aisen
   • A. Sandrock

   Original Research Open access 18 March 2022 Pages: 197 - 210

   

5. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy

   • Jerome Barakos
   • D. Purcell
   • E. Vijverberg

   Review Open access 02 February 2022 Pages: 211 - 220

   

6. Aducanumab: Appropriate Use Recommendations Update

   • Jeffrey Cummings
   • G. D. Rabinovici
   • Alzheimer’s Disease and Related Disorders Therapeutics Working Group

   Special Article Open access 05 April 2022 Pages: 221 - 230

   

7. Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report

   • Serge Gauthier
   • A. Boxer
   • B. Vellas

   Original Research Open access 15 March 2022 Pages: 231 - 235

8. Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)

   • J. Shuren
   • P. M. Doraiswamy

   Point of View 11 March 2022 Pages: 236 - 240

9. Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials

   • J. Cummings

   Point of View Open access 04 February 2022 Pages: 241 - 246

   

10. A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease

    • L. S. Schneider
    • M. Laudon
    • N. Zisapel

    Original Research Open access 23 November 2021 Pages: 247 - 254

    

11. Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial

    • Kathryn V. Papp
    • H. Rofael
    • David Henley

    Original Research 02 February 2022 Pages: 255 - 261

    

12. Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline

    • T. Banh
    • C. Jin
    • R. L. Nosheny

    Original Research Open access 14 December 2021 Pages: 262 - 268

    

13. Validity of Online Versus In-Clinic Self-Reported Everyday Cognition Scale

    • Taylor Howell
    • J. Neuhaus
    • Alzheimer’s Disease Neuroimaging Initiative

    Original Research Open access 31 January 2022 Pages: 269 - 276

    

14. Alzheimer’s Disease Prevention Health Coaching

    • Annie Rhodes
    • J. Inker
    • F. Zanjani

    Original Research 01 April 2022 Pages: 277 - 285

    

15. Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults

    • Catriona K. Lewis
    • O. M. Bernstein
    • D. L. Sultzer

    Original Research 18 January 2022 Pages: 286 - 296

    

16. Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults

    • Jason K. Longhurst
    • J. L. Cummings
    • M. R. Landers

    Original Research 20 January 2022 Pages: 297 - 305

17. Disease Burden and Attributable Risk Factors of Alzheimer’s Disease and Dementia in China from 1990 to 2019

    • R. Li
    • J. Qi
    • Hualiang Lin

    Original Research 19 January 2022 Pages: 306 - 314

    

18. The Association of Heart/Vascular Aging with Mild Cognitive Impairment in a Rural Multiethnic Cohort: The Project FRONTIER Study

    • Duke Appiah
    • G. Ashworth
    • N. Nair

    Original Research 19 January 2022 Pages: 315 - 322

    

19. The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis

    • Q. Sun
    • Y. Yang
    • X. Li

    Original Research 21 January 2022 Pages: 323 - 330

    

20. Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer’s Disease Neuroimaging Initiative Database

    • K. Abe
    • Yuhei Chiba
    • Alzheimer’s Disease Neuroimaging Initiative

    Original Research 26 January 2022 Pages: 331 - 337

    

21. Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer’s Disease Predementia

    • B. Souchet
    • M. Audrain
    • Jérôme Braudeau

    Original Research 19 January 2022 Pages: 338 - 347

    

22. The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland

    • Craig W. Ritchie
    • J. M. J. Waymont
    • A. Kilgour

    Review Open access 01 December 2021 Pages: 348 - 358

    

23. The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis

    • N. Ali
    • H. Tian
    • Tong Wang

    Review 20 January 2022 Pages: 359 - 370

    

24. Identifying Dementia Risk in Older Veterans Using A Mailing Survey

    • A. Shah
    • O. Ysea-Hill
    • Jorge G. Ruiz

    Brief Reports 18 January 2022 Pages: 371 - 375

25. Study Protocol of a Comprehensive Activity Promotion Program for the Prevention of Dementia: A Randomized Controlled Trial Protocol

    • Hiroyuki Shimada
    • S. Lee
    • H. Arai

    Study Protocol 14 January 2022 Pages: 376 - 384